Q3 2024 Brainsway Ltd Earnings Call Transcript
Key Points
- BrainsWay Ltd (BRSYF) reported a 26% year-over-year increase in revenue for Q3 2024, reaching $10.5 million.
- The company achieved positive quarterly net income for the fourth consecutive quarter and positive adjusted EBITDA and cash flow from operations for the fifth consecutive quarter.
- BrainsWay Ltd (BRSYF) has a strong balance sheet with no debt and a cash position of approximately $68.4 million after a strategic private investment equity financing.
- The company is expanding its global distribution and sales network, with recent placements of Deep TMS systems in Taiwan and South Korea.
- BrainsWay Ltd (BRSYF) is conducting a multicenter clinical trial for an accelerated treatment protocol for its Deep TMS system, which could enhance treatment capabilities and appeal to patients.
- Operating expenses increased, with sales and marketing expenses rising to $4.1 million and research and development expenses to $1.8 million for Q3 2024.
- Despite revenue growth, the company faces significant competition in the TMS technology market.
- The geopolitical situation in Israel poses potential risks, although the company has contingency plans in place.
- The company is heavily reliant on enterprise accounts for large and repeat orders, which could be a risk if these relationships change.
- The timeline for FDA approval of new protocols and indications, such as accelerated Deep TMS and adolescent depression treatment, extends into 2025, delaying potential revenue from these innovations.
Good day and welcome to the BrainsWay third quarter 2024 earnings conference call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Brian Ritchie of LifeSci Advisors. Please go ahead.
Thank you, all, and welcome to BrainsWay's third quarter 2024 earnings conference call. With us today are BrainsWay's Chief Executive Officer, Hadar Levy; and Chief Financial Officer, Ido Marom. The format for today's call will be a discussion of recent trends and business updates from Hadar followed by a detailed discussion of the financials. Then, we will open up the call for your questions.
Earlier today, BrainsWay released financial results for the three and nine months ended September 30, 2024. A copy of the press release is available on the company's Investor Relations website.
Before I turn the call over to Hadar, I would like to remind you that this conference call, including both management's prepared remarks and the question
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
